1. Home
  2. INSM vs ONON Comparison

INSM vs ONON Comparison

Compare INSM & ONON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • ONON
  • Stock Information
  • Founded
  • INSM 1988
  • ONON 2010
  • Country
  • INSM United States
  • ONON Switzerland
  • Employees
  • INSM N/A
  • ONON N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • ONON Shoe Manufacturing
  • Sector
  • INSM Health Care
  • ONON Consumer Discretionary
  • Exchange
  • INSM Nasdaq
  • ONON Nasdaq
  • Market Cap
  • INSM 19.1B
  • ONON 19.4B
  • IPO Year
  • INSM 2000
  • ONON 2021
  • Fundamental
  • Price
  • INSM $103.95
  • ONON $50.74
  • Analyst Decision
  • INSM Strong Buy
  • ONON Strong Buy
  • Analyst Count
  • INSM 17
  • ONON 20
  • Target Price
  • INSM $109.20
  • ONON $62.90
  • AVG Volume (30 Days)
  • INSM 4.1M
  • ONON 5.8M
  • Earning Date
  • INSM 08-07-2025
  • ONON 08-12-2025
  • Dividend Yield
  • INSM N/A
  • ONON N/A
  • EPS Growth
  • INSM N/A
  • ONON 61.26
  • EPS
  • INSM N/A
  • ONON 0.71
  • Revenue
  • INSM $381,030,000.00
  • ONON $2,869,732,450.00
  • Revenue This Year
  • INSM $28.17
  • ONON $29.06
  • Revenue Next Year
  • INSM $120.09
  • ONON $24.47
  • P/E Ratio
  • INSM N/A
  • ONON $71.28
  • Revenue Growth
  • INSM 20.77
  • ONON 34.92
  • 52 Week Low
  • INSM $60.40
  • ONON $34.59
  • 52 Week High
  • INSM $106.83
  • ONON $64.05
  • Technical
  • Relative Strength Index (RSI)
  • INSM 66.75
  • ONON 42.15
  • Support Level
  • INSM $101.55
  • ONON $49.61
  • Resistance Level
  • INSM $103.74
  • ONON $54.41
  • Average True Range (ATR)
  • INSM 2.58
  • ONON 1.72
  • MACD
  • INSM -0.49
  • ONON -0.26
  • Stochastic Oscillator
  • INSM 86.11
  • ONON 22.11

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About ONON On Holding AG

On Holding AG is a premium performance sports brand rooted in technology, design, and impact. Its shoes, apparel, and accessories products are designed predominantly for athletic use, casual, or leisure purposes. It does not manufacture the products or the raw materials and relies instead on third-party suppliers and contract manufacturers. Geographically, it derives a majority of its revenue from the Americas and rest from Europe, Middle East and Africa and Asia-Pacific region.

Share on Social Networks: